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The Hippocratic humoral theory is upheld in modern
neuropharmacologic investigations showing depressive
relapse with catecholamine-depleting agents. Serotonin
dysregulation is supported, especially in females, in
reduced 5-HT2A receptors in PET studies. Further-
more, the ancient concept of temperament and its role
in depression is supported by current psychometric
research. Despite increasing clinical and public health
recognition, sophisticated research strategies and the
broad availability of relatively safer agents for treat-
ment, depression continues to be a prevalent group of
illnesses which often pursue a recurrent and chroni-
cally relapsing course with considerable morbidity and
mortality. Etiology is multifactorial, involving, among
others, familial-genetic, demographic, developmental,
personality, seasonal-circadian, experiential, interperso-
nal, conjugal, cultural and economic factors. Grief,
losses and other life events, emphasized in Freud’s and
Bowlby’s writings, as well as current clinical research
experience, together with Darwin’s landmark work on
evolution, place sadness and related emotions in an
adaptive context. Current evidence indicates that
experiencing life events depends on a familial diathesis
for depression, and that temperament increases reac-
tivity to the very life events that precipitate depression.
Even social support, a factor that buffers the depres-
sant effect of life events, appears to be dependent on
familial factors. Finally, a positive family history of
depression, seems to involve the amygdala. It is of
great theoretical and clinical interest that the respon-
sivity of the amygdala is mediated through such condi-
tions as anxiety, bipolar II and related affective
personality styles. Response of aversive stimuli, too,
appears to be processed through the limbic structures.
Many medically associated somatic complaints–fibro-
myalgia, irritable bowel syndrome and migraine–
appear to be part of the foregoing affective spectrum.
Depression may precede, follow or complicate such
common diseases as diabetes, myocardial infarction,
stroke, and treatment of the associated depression
often improves the prognosis of the underlying disease.
Another provocative development is the continuity of
unipolar and bipolarI II doisorders, which may in
selected patients necessitate the use of antidepressant
augmentation strategies.
Current treatment research involves complex meth-
odologies in both the psychosocial and psychopharma-
cologic realms, which each clinician must practice as
an art. Medications are best administered in the con-
text of of an ongoing therapeutic alliance. Prototypes
of modern mood stabilizers [lithium, carbamazepine,
divalproex, topiramate, gabapentin, lamotrigene] are
efficaceous via somewhat overlapping yet distinct
mechanisms. Many antipsychotics [eg, perphenazine,
risperidone, olanzapine, quetiapine, ziprasidone, aripi-
prazole] exercise prominent mood stabilizing effects.
Finally, prototypes of antidepressants exert thymoleptic
action via putative noradrenergic [desipramine], seroto-
ninergic [fluoxetine], or dual chemical action[ venlafax-
ine], possibly dopaminergic [bupropion?], and in the
case of MAOIs such as tranylcypromine appear to
involve all three neurotransmitters. Glutaminergic
action represents a new fascinating vista beyond the
scope of this presentation. Given that mood disorders
do occur in a distinct minority of eminent and creative
individuals, the clinician can appropriately weigh the
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relative advantages and limitations of these agents as
well as their different side-effect profiles for a given
patient in these populations.
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